Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 6/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13499322 | 0.88 | TMEM97 (0.53) | LTA4HTMEM97SIGMAR1KDM4EKCNA5 | |
| SCHEMBL13499489 | 0.79 | KCNA5 (0.55) | KCNA5HTR7DRD2 | |
| SCHEMBL7137971 | 0.77 | LTA4H (0.58) | LTA4HTMEM97SIGMAR1KDM4EKCNH2 | |
| SCHEMBL13499437 | 0.74 | TMEM97 (0.47) | LTA4HTMEM97SIGMAR1KCNH2HTR7 | |
| SCHEMBL13499362 | 0.74 | HTR1A (0.50) | LTA4HTMEM97SIGMAR1KDM4EKCNH2 | |
| SCHEMBL14204682 | 0.74 | LTA4H (0.83) | LTA4HKCNH2HRH3 | |
| SCHEMBL13499492 | 0.72 | HRH3 (0.48) | LTA4HTMEM97SIGMAR1KDM4EKCNH2 | |
| SCHEMBL7399430 | 0.71 | TMEM97 (0.63) | LTA4HTMEM97SIGMAR1KDM4ENPSR1 | |
| SCHEMBL8693002 | 0.71 | HTR7 (0.60) | LTA4HTMEM97SIGMAR1KDM4EKCNA5 | |
| SCHEMBL7139525 | 0.70 | LTA4H (0.80) | LTA4HKCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. | 2010-02-04 | — | — | US | disclosed |
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, ADRB2, CHRNA5 | LTA4H 3480/4885TMEM97 139/4885SIGMAR1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.